Yoon Suk Jung1, Chan Hyuk Park2, Nam Hee Kim1, Jung Ho Park1, Dong Il Park1, Chong Il Sohn1. 1. Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea. Electronic address: yesable7@gmail.com.
Abstract
BACKGROUND: We aimed to develop a combination screening strategy for advanced colorectal neoplasia based on the Asia-Pacific Colorectal Screening score and fecal immunochemical test results. METHODS: We reviewed the records of participants who had undergone a colonoscopy and fecal immunochemical test as part of a comprehensive health screening program. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was analyzed according to Asia-Pacific Colorectal Screening scores and fecal immunochemical test results. RESULTS: We analyzed the data of 9205 participants 40-49 years old and 3215 participants ≥50 years old. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was 1.0%, 2.1%, 7.1%, and 13.4% in the "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening<2," "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening≥2," "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening<2," and "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroups, respectively. The prevalence of advanced colorectal neoplasia in "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroup was higher than in participants ≥50 years old with Asia-Pacific Colorectal Screening≥4 (13.4% vs. 5.8%, P<0.001). CONCLUSIONS: Fecal immunochemical test-positive individuals 40-49 years old with an Asia-Pacific Colorectal Screening≥2 have a higher risk of advanced colorectal neoplasia than individuals ≥50 years old with an Asia-Pacific Colorectal Screening≥4.
BACKGROUND: We aimed to develop a combination screening strategy for advanced colorectal neoplasia based on the Asia-Pacific Colorectal Screening score and fecal immunochemical test results. METHODS: We reviewed the records of participants who had undergone a colonoscopy and fecal immunochemical test as part of a comprehensive health screening program. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was analyzed according to Asia-Pacific Colorectal Screening scores and fecal immunochemical test results. RESULTS: We analyzed the data of 9205 participants 40-49 years old and 3215 participants ≥50 years old. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was 1.0%, 2.1%, 7.1%, and 13.4% in the "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening<2," "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening≥2," "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening<2," and "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroups, respectively. The prevalence of advanced colorectal neoplasia in "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroup was higher than in participants ≥50 years old with Asia-Pacific Colorectal Screening≥4 (13.4% vs. 5.8%, P<0.001). CONCLUSIONS: Fecal immunochemical test-positive individuals 40-49 years old with an Asia-Pacific Colorectal Screening≥2 have a higher risk of advanced colorectal neoplasia than individuals ≥50 years old with an Asia-Pacific Colorectal Screening≥4.
Authors: Jennifer Anne Cooper; Ronan Ryan; Nick Parsons; Chris Stinton; Tom Marshall; Sian Taylor-Phillips Journal: BMC Gastroenterol Date: 2020-03-25 Impact factor: 3.067